Most clinical operations teams treat SCOPE Summit as a checklist for trial design and site management. That’s a mistake. If you’re not looking at SCOPE through the lens of market access, you’re missing the point of why your trial exists in the first place.
I’ve spent 11 years in pharma comm ops and managed markets. I’ve moved from spreadsheets to strategy, and one thing remains constant: if you don’t bake commercial reality into your clinical protocol, you are building a product that no one will pay for. ...where was I?. Don’t tell me about "synergy." Tell me about the HTA landscape.
Here is how to extract actual value from SCOPE to ensure your clinical development program survives the cold, hard reality of the payer environment.
1. Access Input to Protocol: Start Early
Clinical development teams love to talk about "prescriber reach." That’s fine for the KOLs, but it’s useless if the health system pharmacy director won't put your drug on the formulary. You need to start your access input to protocol strategy at the Phase II level.
At SCOPE, stop looking for shiny new site-monitoring software and start looking for people who understand the patient journey within large IDNs. If your protocol requires a Click here for more patient to come in for four different biopsies, you’ve just created a "resource use" nightmare that will kill your formulary bid. Payer committees look at total cost of care. If your clinical trial process creates administrative burden that isn't standard of care, your drug is already losing the battle.
2. The "Who You Actually Meet" Spreadsheet
I keep a running spreadsheet for every conference. You should too. Stop collecting business cards and start collecting intelligence. After SCOPE, my spreadsheet doesn't have a column for "networking." It has a column for "What is this person's power to change site behavior?"
3. THMA, AMCP, and ACCC: Bridging the Gap
When you walk the floor at SCOPE, look for the touchpoints between clinical development and the organizations that actually drive adoption.
- AMCP (Academy of Managed Care Pharmacy): Look for sessions or vendors that discuss managed care strategy. If the evidence you’re generating in your trial isn’t structured for a budget impact model, an AMCP-style review will flag it immediately. The Health Management Academy (THMA): This is your window into the health system executive mindset. If you aren't talking to people who understand how THMA-affiliated health systems handle high-cost specialty drugs, you are building a clinical trial in a vacuum. Association of Cancer Care Centers (ACCC): If you’re in oncology, the ACCC members are the ones running the infusion centers. If your protocol requires a patient to sit in a chair for six hours, the ACCC network will reject it during operational feasibility.
4. RWE Planning and Digital Evidence
RWE planning is no longer an "afterthought" you bolt onto the end of a trial. It’s the backbone of your reimbursement strategy. Digital tools in evidence generation—wearables, ePRO, and remote monitoring—are great, but they have to be integrated into the provider's workflow.
I find it ironic that we talk about affordability and access strategy sophisticated digital evidence while many clinical sites still rely on clunky, legacy web interfaces. You’ll see it at SCOPE—booths demoing sites where you have to click through a dozen "Cookie Law Info" plugin UI elements just to see a basic patient portal. If your trial’s digital data capture is that cumbersome, your site staff won't use it, and your data quality will crater. Real-world evidence requires real-world usability.
5. Pricing, Affordability, and HTA Pressure
If your clinical trial doesn't include resource use endpoints that mirror real-world economic data, you are handing a gift to the HTA (Health Technology Assessment) bodies. They will look at your clinical efficacy and say, "That's nice, but what does it cost the system?"
Your protocol should measure:
Number of unscheduled outpatient visits. Frequency of follow-up diagnostic procedures. Time to treatment initiation (specifically the administrative lag).If you don’t have these endpoints, your commercial team will have to build a shaky "value story" based on assumptions. Do not make them do that. Give them the data.
The "Monday Morning" Reality Check
Every time I leave a conference, I ask myself the same question: "What would I do differently on Monday?"
If your answer is "follow up with leads," you’ve failed. If your answer is "schedule a meeting with the Head of Clinical Development to show them why our secondary endpoints need to include cost-of-care metrics," then you’ve actually brought something back from SCOPE.
Stop focusing on "streamlining" the trial. Focus on making the trial relevant to the people who control the money. If the payer doesn't see the value, the patient won't get the drug, and your "clinical success" will be a commercial failure.
Be blunt. Be specific. And stop pretending that a cocktail hour is a strategy.